Warfarin Reversal for GI Bleeding With a Mechanical Mitral Valve
A 68-year-old woman with a St. Jude mechanical mitral valve placed in 2016 and atrial fibrillation takes warfarin, with a usual INR of 2.5–3.5. She presents after two episodes of melena and one near-syncope. She takes metoprolol and furosemide and has no history of ulcer disease. Blood pressure is 102/64 mmHg, heart rate 108 beats/min, and she is pale and diaphoretic. Hemoglobin is 7.2 g/dL (baseline 12.4), platelets 180,000/µL, INR 4.8, blood urea nitrogen 48 mg/dL, and creatinine 1.1 mg/dL. She has an IV, type and screen has been sent, and the gastroenterology team is arranging endoscopy. She weighs 62 kg and has no known liver disease. The emergency physician must decide how to reverse her anticoagulation and when it can be restarted, knowing that both bleeding and valve thrombosis are real dangers.
1. What is your immediate reversal strategy? Specify agents, dosing rationale, target INR, and why fresh frozen plasma alone is inadequate.
Read the worked answer
This is a major bleed with hemodynamic compromise and an INR of 4.8. Stabilize first: two large-bore IVs, type and crossmatch, RBC transfusion to a restrictive threshold (usually hemoglobin 7–8 g/dL), and urgent gastroenterology involvement. Hold warfarin. Give 4-factor prothrombin complex concentrate, roughly 25–50 units/kg based on INR and weight, plus vitamin K 5–10 mg IV. The target is an INR below 1.5.
PCC is preferred over fresh frozen plasma because it replaces all vitamin K–dependent factors rapidly, in a small volume, without thawing delay, and reliably corrects the INR; FFP in a 62-kg patient would require roughly 15–20 mL/kg (about 1 liter), risks volume overload, and may not achieve the target quickly. Vitamin K is essential because PCC has a short half-life and the INR will rebound without it. Do not use recombinant factor VIIa as first-line therapy. Give platelets if the count is below 50,000/µL, and reverse any other anticoagulant or antiplatelet effect. Endoscopy should proceed once she is stabilized.
2. When and how would you restart anticoagulation? Does the mechanical mitral valve change the decision, and what is the role of bridging?
Read the worked answer
Restart anticoagulation when hemostasis is secure, usually 7–14 days after a gastrointestinal bleed, guided by endoscopic findings and the clinical course. She has a mechanical mitral valve plus atrial fibrillation, so her thrombotic risk is high-warfarin should not be permanently stopped, and a DOAC is contraindicated with a mechanical valve. The safest approach is a shared decision with cardiology, gastroenterology, and the patient.
Bridging with therapeutic low-molecular-weight heparin or unfractionated heparin during the warfarin-free interval is often considered in high-risk mechanical valves, although evidence for bridging is weak and it increases rebleeding. If used, it should start only after bleeding is controlled. Restart warfarin at her prior dose and overlap with heparin until the INR is in the 2.5–3.5 range. Treat the ulcer (PPI, H. pylori testing) and correct modifiable bleeding risks. If she rebleeds, do not abandon anticoagulation; involve cardiology to consider the valve type, position, and alternative strategies, and discuss the competing risks explicitly.
3. How would your answer change if she had a bioprosthetic mitral valve instead?
Read the worked answer
With a bioprosthetic mitral valve, the acute reversal is the same-PCC plus vitamin K for major bleeding-but the long-term plan is simpler. If she has atrial fibrillation and no mechanical valve, a DOAC is appropriate and preferred over warfarin, assuming no severe mitral stenosis or other contraindication. Restarting can often follow the same 7–14-day hemostasis rule, but routine bridging is not needed because the thrombotic risk is lower. If she did not have atrial fibrillation and the bioprosthesis was placed more than 3 months ago, long-term anticoagulation might not be needed at all; aspirin or no antithrombotic therapy may be sufficient depending on the valve and her risk. This contrast matters: the presence of a mechanical valve is what makes DOACs inappropriate and makes bridging a consideration.